The Eastern Cooperative Oncology Group (ECOG) ACRIN trial E1412 study indicated a potential clinical benefit of including LEN 25 mg/day on days 1-10 of each R-CHOP cycle, with a 34% reduction in risk of progression or death compared with R-CHOP alone and improved PFS in patients with DLBCL (activated B-cell subtype).18 In contrast, the ROBUST study reported no improvement in efficacy when adding LEN 15 mg/day on days 1-14 of each cycle vs R-CHOP alone.19 The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.